Evidence map›Paper›PMID 31970477›Full record

Trial reportJournal of bone and mineral metabolism2020

Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.

Satoshi Soen, Kazuhiko Yamamoto, Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Masako Ito, Tetsuo Nakano, Hiroshi Hagino, Akihiro Hirakawa, Toshio Matsumoto

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of bone and mineral metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Satoshi SoenDepartment of Orthopaedic Surgery and Rheumatology, KINDAI University Nara Hospital, Nara, Japan. nra48207@nifty.com.
Kazuhiko YamamotoDepartment of Allergy and Rheumatology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Yoshiya TanakaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Sakae TanakaDepartment of Orthopaedic Surgery, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Masako ItoNagasaki Study Center, The Open University of Japan, Nagasaki, Japan.
Tetsuo NakanoDepartment of Orthopaedic Surgery, Tamana Central Hospital, Kumamoto, Japan.
Hiroshi HaginoSchool of Health ScienceFaculty of Medicine, Tottori University, Tottori, Japan.
Akihiro HirakawaDepartment of Biostatistics and Bioinformatics, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Toshio MatsumotoFujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, Japan.
The University of Tokyo · JPKeio University · JPKumamoto Central Hospital · JPNara Medical University Hospital · JPThe Open University of Japan · JPTokushima University · JPTottori University · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

Ono Pharmaceutical None
6 · The paper itself

Abstract

introductionThis study compared the clinical usefulness of minodronate (50 mg/4 weeks) plus alfacalcidol (1 μg/day) (Group M) with that of alfacalcidol alone (1 μg/day) (Group A) for treating glucocorticoid-induced osteoporosis. MATERIALS AND

methodsThe primary endpoints were the changes from baseline in lumbar spine (LS) bone mineral density (BMD) and the cumulative incidence of vertebral fracture at 24 months; secondary endpoints included the changes from baseline in total hip (TH) BMD and bone turnover markers.

resultsOf 164 patients enrolled, 152 (Group M, n = 75; Group A, n = 77) were included in the analysis of efficacy. At each time point and at 24 months, LS BMD and TH BMD were significantly higher in Group M than in Group A. The 152 patients were divided into two subgroups that were previously treated with glucocorticoids for ≤ 3 months or > 3 months. In both subgroups, the changes from baseline in LS BMD and TH BMD from baseline at 24 months had increased more in Group M than in Group A. There were no differences found in the incidence of vertebral fracture between the groups, because the number of enrolled patients was lesser than that initially expected. In Group M, both bone formation and resorption markers significantly decreased from baseline at 3 months and maintained at 6, 12, and 24 months.

conclusionsMinodronate plus alfacalcidol was more effective than alfacalcidol alone in increasing BMD and was effective in increasing BMD for both prevention and treatment. Therefore, minodronate can be a good candidate drug for the treatment of glucocorticoid-induced osteoporosis.

Indexed as

AdultAgedAged, 80 and overBiomarkersBone DensityBone Density Conservation AgentsBone RemodelingDiphosphonatesDrug Therapy, CombinationFemaleGlucocorticoidsHumansHydroxycholecalciferolsImidazolesMaleMiddle AgedalfacalcidolBiomarkersBone Density Conservation AgentsDiphosphonatesGlucocorticoidsHydroxycholecalciferolsImidazolesYM 529AlfacalcidolBone mineral densityBone turnover markersGlucocorticoid-induced osteoporosisMinodronate

Identifiers

PMID31970477
OpenAlexW3002708394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.